Kymera Therapeutics (KYMR) Fundamental Analysis: Revenue, Earnings & Valuation

3.05 / 10

Netural

Fundamental rating is Neutral with a 3/10 score, indicating weak conditions. Revenue‑MV and Profit‑MV are modestly positive, while Asset‑MV and Fixed‑asset turnover lag. Inventory turnover is strong, but gross margin at 100% and high tax ratio dampen outlook.

Analysis Checks(6/10)

Revenue-MV

Value-5.28

Score2/3

Weight17.84%

1M Return8.05%

Inventory turnover ratio

Value106.57

Score3/3

Weight15.44%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.27%

1M Return1.67%

Profit-MV

Value0.68

Score2/3

Weight14.52%

1M Return6.36%

Income tax / Total profit (%)

Value22.35

Score1/3

Weight0.36%

1M Return0.21%

Current assets turnover ratio

Value0.06

Score1/3

Weight-0.32%

1M Return-0.17%

Fixed assets turnover ratio

Value0.43

Score1/3

Weight-1.89%

1M Return-1.13%

Cost of sales ratio (%)

Value57.03

Score3/3

Weight7.67%

1M Return4.08%

Asset-MV

Value-0.55

Score1/3

Weight28.88%

1M Return11.48%

Cash-MV

Value0.03

Score2/3

Weight14.23%

1M Return6.19%

Is KYMR fundamentally strong?

KYMR scores 3.05/10 on fundamentals and holds a Fair valuation at present. Backed by its -25.78% ROE, -794.04% net margin, -20.50 P/E ratio, 4.04 P/B ratio, and -23.83% earnings growth, these metrics solidify its Netural investment rating.